Classification of Lung Cancer

Seminars in Roentgenology

Volumn 46, Issue 3, 2011, Pages 178-186

  Travis, William D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PEMETREXED; PROTEIN P63; PROTEIN TYROSINE KINASE INHIBITOR; THYROID TRANSCRIPTION FACTOR 1;

ADENOCARCINOMA IN SITU; ADENOSQUAMOUS CARCINOMA; ADVANCED CANCER; ARTICLE; ATYPICAL ADENOMATOUS HYPERPLASIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CARCINOID; CARCINOMA IN SITU; CLINICAL FEATURE; CYTODIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DIFFUSE IDIOPATHIC PULMONARY NEUROENDOCRINE CELL HYPERPLASIA; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SARCOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MINIMALLY INVASIVE ADENOCARCINOMA; NEUROENDOCRINE TUMOR; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BIOPSY; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROGNOSIS; TERMINOLOGY AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 79959872486     PISSN: 0037198X     EISSN: 15584658     Source Type: Journal    
DOI: 10.1053/j.ro.2011.02.003     Document Type: Article

References (65)

1. Travis W.D., Brambilla E., Noguchi M., et al. International association for the study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
2. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
4. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Zhou C., Wu Y.-L., Chen G., et al. Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010, 21:LBA13.
6. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
7. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009, 374. 14321420.
8. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 2009, 14:253-263.
9. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
10. Aberle D.R., Berg C.D., Black W.C., et al. The National Lung Screening Trial: Overview and Study design. Radiology 2011, 258:243-253. National Lung Screening Trial Research Team.
11. Travis W.D., Brambilla E., Müller-Hermelink H.K., et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC, Lyon.
12. Colby T.V., Koss M.N., Travis W.D. Tumors of the Lower Respiratory Tract; Armed Forces Institute of Pathology Fascicle, Third Series 1995, Armed Forces Institute of Pathology, Washington, DC.
13. Johnston W.W., Frable W.J. The cytopathology of the respiratory tract. A review. Am J Pathol 1976, 84:372-424.
14. Edell E., Lam S., Pass H., et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: An international, multicenter clinical trial. J Thorac Oncol 2009, 4:49-54.
15. Kennedy T.C., McWilliams A., Edell E., et al. Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:221S-233S. (2nd edition).
16. Henschke C.I., Yankelevitz D.F. Screening for lung cancer: Update 2007. Oncologist 2008, 13:65-78.
17. Travis W.D., Brambilla E. Pathology of Lung Preneoplasia. Textbook of Prevention and Detection of Early Lung Cancer; International Association for the Study of Lung Cancer 2006, 75-89. Taylor & Francis, London and New York. F.R. Hirsch (Ed.).
18. Miller R.R. Bronchioloalveolar cell adenomas. Am J Surg Pathol 1990, 14:904-912.
19. Weng S.Y., Tsuchiya E., Kasuga T., et al. Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: Relation to histological subtypes of lung cancer. Virchows Arch A Pathol Anat Histopathol 1992, 420:463-471.
20. Carey F.A., Wallace W.A., Fergusson R.J., et al. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: A clinicopathological study of 10 cases. Thorax 1992, 47:1041-1043.
21. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990, 114:363-368.
22. Watanabe S., Watanabe T., Arai K., et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002, 73:1071-1075.
23. Sakurai H., Dobashi Y., Mizutani E., et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: A prognostic assessment. Ann Thorac Surg 2004, 78:1728-1733.
24. Vazquez M., Carter D., Brambilla E., et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implications. Lung Cancer 2009, 64:148-154.
25. Yamato Y., Tsuchida M., Watanabe T., et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001, 71:971-974.
26. Yoshida J., Nagai K., Yokose T., et al. Limited resection trial for pulmonary ground glass opacity nodules: Fifty-case experience. J Thorac Cardiovasc Surg 2005, 129:991-996.
27. Koike T., Togashi K., Shirato T., et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg 2009, 88:1106-1111.
28. Noguchi M., Morikawa A., Kawasaki M., et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75:2844-2852.
29. Yim J., Zhu L.C., Chiriboga L., et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007, 20:233-241.
30. Aguayo S.M., Miller Y.E., Waldron J.A., et al. Brief report: Idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 1992, 327:1285-1288.
31. Davies S.J., Gosney J.R., Hansell D.M., et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: An under-recognised spectrum of disease. Thorax 2007, 62:248-252.
32. Koo C.W., Baliff J.P., Torigian D.A., et al. Spectrum of pulmonary neuroendocrine cell proliferation: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol 2010, 195:661-668.
33. Altekruse S.F., Kosary C.L., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute http://seer.cancer.gov/csr/1975_2007/.
34. Tomashefski J.F., Connors A.F., Rosenthal E.S., et al. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med 1990, 114:468-474.
35. Yousem S.A. Peripheral squamous cell carcinoma of lung: Patterns of growth with particular focus on airspace filling. Hum Pathol 2009, 40:861-867.
36. Sakurai H., Asamura H., Watanabe S., et al. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg 2004, 78:222-227.
37. Churg A., Johnston W.H., Stulbarg M. Small cell squamous and mixed small cell squamous-Small cell anaplastic carcinomas of the lung. Am J Surg Pathol 1980, 4:255-263.
38. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75:191-202. [Published erratum appears in Cancer 1995 75(12):2979].
39. Yoshizawa A, Motoi N, Riely GJ, et al: Prognostic significance of the proposed IASLC/ATS/ERS revised classification of lung adenocarcinoma in 514 stage I lung adenocarcinomas. Mod Pathol, in press.
40. Suzuki K., Yokose T., Yoshida J., et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000, 69:893-897.
41. Sakurai H., Maeshima A., Watanabe S., et al. Grade of stromal invasion in small adenocarcinoma of the lung: Histopathological minimal invasion and prognosis. Am J Surg Pathol 2004, 28:198-206.
42. Borczuk A.C., Qian F., Kazeros A., et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009, 33:462-469.
43. Solomon S.B., Zakowski M.F., Pao W., et al. Core Needle Lung Biopsy Specimens: Adequacy for EGFR and KRAS Mutational analysis. AJR Am J Roentgenol 2010, 194:266-269.
44. Kreisman H., Wolkove N., Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992, 101:225-231.
45. Gephardt G.N., Grady K.J., Ahmad M., et al. Peripheral small cell undifferentiated carcinoma of the lung. Clinicopathologic features of 17 cases. Cancer 1988, 61:1002-1008.
46. Nicholson S.A., Beasley M.B., Brambilla E., et al. Small Cell Lung Carcinoma (SCLC): A Clinicopathologic Study of 100 Cases with Surgical Specimens. Am J Surg Pathol 2002, 26:1184-1197.
47. Travis W.D. Advances in neuroendocrine lung tumors. Ann Oncol 2010, 7(21 suppl):vii65-vii71.
48. Folpe A.L., Gown A.M., Lamps L.W., et al. Thyroid transcription factor-1: Immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999, 12:5-8.
49. Sturm N., Rossi G., Lantuejoul S., et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002, 33:175-182.
50. Sturm N., Lantuejoul S., Laverriere M.H., et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001, 32:918-925.
51. Rossi G., Marchioni A., Milani M., et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004, 122:884-893.
52. Carvalho L. Reclassifying bronchial-pulmonary carcinoma: Differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol 2009, 15:1101-1119.
53. Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978, 9:143-156.
54. Hammar S.P., Bolen J.W., Bockus D., et al. Ultrastructural and immunohistochemical features of common lung tumors: An overview. Ultrastruct Pathol 1985, 9:283-318.
55. Mackay B., Ordónez N.G., Bennington J.L., et al. Ultrastructural and morphometric features of poorly differentiated and undifferentiated lung tumors. Ultrastruct Pathol 1989, 13:561-571.
56. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934-944.
57. Travis W.D., Krug L.M., Rusch V. Large cell neuroendocrine carcinoma. Textbook of Uncommon Cancer 2006, 298-306. John Wiley & Sons, Ltd, Chichester, West Sussex, England. D. Raghavan, M.L. Brecher, D.H. Johnson (Eds.).
58. Moro-Sibilot D., Lantuejoul S., Diab S., et al. Lung carcinomas with a basaloid pattern: A study of 90 cases focusing on their poor prognosis. Eur Respir J 2008, 31:854-859.
59. Chang Y.L., Wu C.T., Shih J.Y., et al. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci 2011, 102:282-287.
60. Chang Y.L., Wu C.T., Shih J.Y., et al. New Aspects in Clinicopathologic and Oncogene Studies of 23 Pulmonary lymphoepithelioma-like Carcinomas. Am J Surg Pathol 2002, 26:715-723.
61. Katzenstein A.L., Prioleau P.G., Askin F.B. The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer 1980, 45:943-947.
62. Izquierdo-Garcia F.M., Moreno-Mata N., Herranz-Aladro M.L., et al. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment. Histol Histopathol 2010, 25:1287-1295.
63. Travis W.D. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009, 1(45 suppl):251-266.
64. Cooke D.T., Nguyen D.V., Yang Y., et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010, 90:943-948.
65. Travis W.D. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med 2010, 134:1645-1658.